Suppr超能文献

工程植物为生产各种人乳寡糖提供了一个光合作用平台。

Engineered plants provide a photosynthetic platform for the production of diverse human milk oligosaccharides.

机构信息

Department of Plant and Microbial Biology, University of California, Berkeley, Berkeley, CA, USA.

Department of Plant Biology, University of California, Davis, Davis, CA, USA.

出版信息

Nat Food. 2024 Jun;5(6):480-490. doi: 10.1038/s43016-024-00996-x. Epub 2024 Jun 13.

Abstract

Human milk oligosaccharides (HMOs) are a diverse class of carbohydrates which support the health and development of infants. The vast health benefits of HMOs have made them a commercial target for microbial production; however, producing the approximately 200 structurally diverse HMOs at scale has proved difficult. Here we produce a diversity of HMOs by leveraging the robust carbohydrate anabolism of plants. This diversity includes high-value and complex HMOs, such as lacto-N-fucopentaose I. HMOs produced in transgenic plants provided strong bifidogenic properties, indicating their ability to serve as a prebiotic supplement with potential applications in adult and infant health. Technoeconomic analyses demonstrate that producing HMOs in plants provides a path to the large-scale production of specific HMOs at lower prices than microbial production platforms. Our work demonstrates the promise in leveraging plants for the low-cost and sustainable production of HMOs.

摘要

人乳寡糖(HMOs)是一类具有多种功能的碳水化合物,能够支持婴儿的健康和发育。HMOs 具有巨大的健康益处,这使其成为微生物生产的商业目标;然而,大规模生产结构上大约有 200 种不同的 HMOs 一直以来都非常困难。在这里,我们利用植物强大的碳水化合物合成能力来生产多种 HMOs。这种多样性包括高价值和复杂的 HMOs,如乳-N-岩藻五糖 I。在转基因植物中生产的 HMOs 具有很强的双歧杆菌增殖特性,这表明它们能够作为一种益生元补充剂,具有在成人和婴儿健康方面的潜在应用。技术经济分析表明,在植物中生产 HMOs 提供了一种以低于微生物生产平台的价格大规模生产特定 HMOs 的途径。我们的工作证明了利用植物来低成本、可持续地生产 HMOs 的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b224/11199141/291ed51ea155/43016_2024_996_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验